Perturbed actin cap as a new personalized biomarker in primary fibroblasts of Huntington’s disease patients

Saja Gharaba, Omri Paz, Lea Feld, Anastasia Abashidze, Maydan Weinrab, Noam Muchtar, Adam Baransi, Aviv Shalem, Uri Sprecher, Lior Wolf, Haguy Wolfenson, Miguel WeilFrontiers in Cell and Developmental Biology 2023 · DOI

TL;DR

Researchers have discovered that skin cells from Huntington’s Disease (HD) patients possess a structural defect: a deficient "actin cap" over the nucleus. This morphological signature correlates with clinical disease severity and impaired cell motility, providing a non-invasive, personalized platform for screening potential drugs.

What Problem Does This Paper Address?

Huntington’s Disease (HD) is a devastating neurodegenerative disorder caused by a genetic expansion of CAG repeats. While it is primarily defined by brain pathology, the mutated protein (mHtt) is expressed throughout the body. Currently, we lack non-invasive, personalized biomarkers that can track disease progression or predict how a specific patient might respond to a drug.

The authors set out to find a "cellular signature" in primary skin fibroblasts—cells that are easy to collect via biopsy and retain the patient's unique genetic and biochemical profile. By identifying a visible structural flaw in these accessible cells, they hope to create a "clinical trial in a dish" for personalized medicine.

Methods

The study utilized Image-Based High-Content Analysis (HCA) to perform unbiased screening of thousands of cells. Key techniques included:

  • Primary Cell Culture: Fibroblasts from HD patients, healthy controls (HC), and Hutchinson-Gilford Progeria Syndrome (HGPS) patients (used as a known reference for nuclear defects).
  • Custom 2D Image Analysis: The team developed a Python-based tool (using OpenCV) to quantify nuclear circularity and the "slope" (parallelism) of actin fibers.
  • Confocal Microscopy: 3D z-stack imaging was used to specifically visualize the actin cap—a dome of contractile fibers that normally sits atop the nucleus, regulating its shape and protecting the genome.
  • Drug Perturbation: Cells were treated with Latrunculin B (to disrupt actin) and MitoQ (an antioxidant) to see if the biomarker was responsive to pharmacological intervention.

Datasets

The researchers analyzed a robust cohort of primary human samples:

  • HD Group: 28 patients across different stages (premanifest, mild, and severe).
  • Healthy Controls: 19 age-matched individuals.
  • Positive Control: 6 HGPS (Progeria) patients, known for severe actin cap deficiencies.
  • Young Controls: 4 healthy young individuals. Samples were sourced from major repositories like the Coriell Institute and the NIA.

Key Insights and Ideas

  • The Progeria Connection: One of the most striking "aha moments" was the resemblance between HD cells and Progeria cells. Both exhibit a "bald" nucleus lacking the apical actin cap, leading to more rounded, less oval nuclei.
  • Morphology as a Proxy for Severity: The study found a direct correlation between the cellular defect and the patient's clinical status. As the disease severity (measured by the clinical CAP score) increased, the actin cap became more disorganized and the nucleus more circular.
  • Structural-Functional Link: The loss of the actin cap isn't just a visual marker; it has functional consequences. HD cells showed significantly reduced migratory capacity (motility), likely because the actin cap is essential for transmitting forces during cell movement.
  • A Dynamic Biomarker: The defect is not permanent. Treatment with the antioxidant MitoQ partially restored the actin cap and improved nuclear morphology, suggesting this platform can measure drug efficacy in real-time.

Key Results

  • Clear Segregation: Principal Component Analysis (PCA) of the phenotypic data successfully separated HD cells from healthy controls with a 64% variance ratio.
  • Nuclear Rounding: HD fibroblasts showed significantly higher "roundness" (form factor) compared to controls ($p < 0.001$).
  • Actin Intensity: Confocal analysis revealed that F-actin intensity at the apical surface of the nucleus was significantly lower in HD and HGPS cells compared to healthy controls.
  • Clustering Success: K-means clustering identified a specific phenotype (Cluster 2) that contained 70.3% of the HD cells but only 29.7% of the controls, characterized by small, circular nuclei and disorganized actin.

Limitations and Future Work

While the study establishes a strong correlation, the exact molecular mechanism by which mutant Huntingtin disrupts the actin cap remains a hypothesis (potentially involving interference with $\alpha$-actinin).

Additionally, while the 2D analysis tool is efficient for high-throughput screening, the authors acknowledge that the actin cap is a 3D structure. Future iterations of their software could incorporate automated 3D segmentation to capture even finer details. The ultimate goal is to use this fibroblast platform to screen large libraries of compounds to identify personalized treatments for HD patients before they ever enter a clinical trial.

Summary updated

Abstract

Primary fibroblasts from patient's skin biopsies are directly isolated without any alteration in the genome, retaining in culture conditions their endogenous cellular characteristics and biochemical properties. The aim of this study was to identify a distinctive cell phenotype for potential drug evaluation in fibroblasts from Huntington's Disease (HD) patients, using image-based high content analysis. We show that HD fibroblasts have a distinctive nuclear morphology associated with a nuclear actin cap deficiency. This in turn affects cell motility in a similar manner to fibroblasts from Hutchinson-Gilford progeria syndrome (HGPS) patients used as known actin cap deficient cells. Moreover, treatment of the HD cells with either Latrunculin B, used to disrupt actin cap formation, or the antioxidant agent Mitoquinone, used to improve mitochondrial activity, show expected opposite effects on actin cap associated morphological features and cell motility. Deep data analysis allows strong cluster classification within HD cells according to patients' disease severity score which is distinct from HGPS and matching controls supporting that actin cap is a biomarker in HD patients' cells correlated with HD severity status that could be modulated by pharmacological agents as tool for personalized drug evaluation.
BibTeX
@inproceedings{gharaba2023perturbed,
  author = {Saja Gharaba and Omri Paz and Lea Feld and Anastasia Abashidze and Maydan Weinrab and Noam Muchtar and Adam Baransi and Aviv Shalem and Uri Sprecher and Lior Wolf and Haguy Wolfenson and Miguel Weil},
  title = {{Perturbed actin cap as a new personalized biomarker in primary fibroblasts of Huntington’s disease patients}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2023},
  doi = {10.3389/fcell.2023.1013721},
}
Figure